| Name | Title | Contact Details |
|---|
AirBoss of America Corp. is a leading developer and manufacturer of advanced custom rubber compounds and finished rubber products. Founded in 1989 and headquartered in Newmarket, Ontario, Canada, the company operates multiple facilities in Canada and the United States. Originally known as IATCO Industries Inc., AirBoss has grown from manufacturing segmented tires to providing innovative solutions in industrial rubber products, personal protective equipment (PPE), and survivability solutions. The company offers a diverse range of products across various industries. This includes rubber compounds for automotive, heavy industry, and construction, as well as PPE for military, law enforcement, and healthcare professionals. AirBoss also develops survivability solutions, such as rapid deployment negative pressure isolation shelters. With a focus on quality and innovation, AirBoss serves customers in automotive, healthcare, defense, and industrial sectors, ensuring safety and reliability in their products. The company operates through several subsidiaries, enhancing its capabilities in rubber compounding and defense-related solutions.
ACTS is a 35-year-old nonprofit based in the Commonwealth of Virginia (U.S.A.) that is supported by all of the worlds leading light car and truck makers. Our mission is to research, educate and promote highway and motor vehicle safety.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Brown & Brown is a prominent insurance brokerage firm based in Daytona Beach, Florida, with a history that dates back to 1939. Originally founded as Brown & Owen, the company has grown to become one of the largest insurance intermediaries globally and is publicly traded on the NYSE under the ticker BRO. It has been part of the S&P 500 since 2021 and has earned recognition as a Great Place to Work Certified™ company since 2018. The company operates through four main business segments: Business Insurance, which offers tailored risk management solutions; Personal Insurance, providing coverage for high-net-worth individuals; Programs & Underwriting, managing niche insurance programs; and Wholesale Brokerage, serving as an intermediary for agents and carriers. Brown & Brown emphasizes a customer-focused approach and has achieved significant growth through both organic expansion and strategic acquisitions. Its diverse service offerings cater to businesses, individuals, and insurance agents, reinforcing its position as a leader in the insurance industry.